Effects of Lactotripeptide Supplementation on Tele-Monitored Home Blood Pressure and on Vascular and Renal Function in Prehypertension　- Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study

Overview

Journal Circ Rep

Date 2021 Mar 11

PMID 33693081

Authors

Hirofumi Tomiyama

Masatsune Fujii

Kazuki Shiina

Shin-Ichiro Ueda

Yoichi Iwasaki

Chisa Matsumoto

Taishiro Chikamori

Affiliations

Soon will be listed here.

Abstract

This randomized, double-blind, placebo-controlled, cross-over study was conducted to examine the effects of lactotripeptide supplementation on 7-day mean tele-monitored home blood pressure (BP), and also on the markers of vascular function and renal damage in Japanese subjects with prehypertension. A total of 26 subjects with prehypertension were randomly allocated to receive the active product (lactotripeptide tablet) or a placebo tablet for 8 weeks each in a cross-over manner. Urinary liver-type fatty acid-binding protein-to-creatine ratio (UFABPCR) and vascular function were measured at the end of each intervention. Home systolic and diastolic BP at the end of the lactotripeptide supplementation period was significantly lower than that at the end of the placebo period (P<0.05). On mixed linear model analysis there was a significant difference in the change in home diastolic BP after intervention between the 2 interventions (P=0.04). UFABPCR was significantly lower at the end of the lactotripeptide intervention period than at the end of the placebo period (P<0.05). The beneficial effect of lactotripeptide supplementation on 7-day mean tele-monitored home BP was confirmed in Japanese subjects with prehypertension. In addition, this intervention also seemed to have a protective effect against the progression of renal function decline.

References

Tomiyama H, Yoshida M, Higashi Y, Takase B, Furumoto T, Kario K . Autonomic nervous activation triggered during induction of reactive hyperemia exerts a greater influence on the measured reactive hyperemia index by peripheral arterial tonometry than on flow-mediated vasodilatation of the brachial artery in.... Hypertens Res. 2014; 37(10):914-8. DOI: 10.1038/hr.2014.103. View

Tomiyama H, Kohro T, Higashi Y, Takase B, Suzuki T, Ishizu T . Reliability of measurement of endothelial function across multiple institutions and establishment of reference values in Japanese. Atherosclerosis. 2015; 242(2):433-42. DOI: 10.1016/j.atherosclerosis.2015.08.001. View

Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M . The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res. 2014; 37(4):253-390. DOI: 10.1038/hr.2014.20. View

Quaschning T, Ruschitzka F, Luscher T . Vasopeptidase inhibition: effective blood pressure control for vascular protection. Curr Hypertens Rep. 2002; 4(1):78-84. DOI: 10.1007/s11906-002-0057-7. View

Ohkubo T, Mihailidou A . Is there a role for day-to-day home blood pressure variability in guiding management of hypertension?. Clin Exp Pharmacol Physiol. 2013; 41(1):54-7. DOI: 10.1111/1440-1681.12172. View

Oza R, Garcellano M . Nonpharmacologic management of hypertension: what works?. Am Fam Physician. 2015; 91(11):772-6. View

Cicero A, Aubin F, Azais-Braesco V, Borghi C . Do the lactotripeptides isoleucine-proline-proline and valine-proline-proline reduce systolic blood pressure in European subjects? A meta-analysis of randomized controlled trials. Am J Hypertens. 2013; 26(3):442-9. PMC: 3565599. DOI: 10.1093/ajh/hps044. View

Qin L, Xu J, Dong J, Zhao Y, van Bladeren P, Zhang W . Lactotripeptides intake and blood pressure management: a meta-analysis of randomised controlled clinical trials. Nutr Metab Cardiovasc Dis. 2013; 23(5):395-402. DOI: 10.1016/j.numecd.2013.02.006. View

Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai T, Hirose K . Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res. 2002; 25(3):359-64. DOI: 10.1291/hypres.25.359. View

10.

Yamasue K, Morikawa N, Mizushima S, Tochikubo O . The blood pressure lowering effect of lactotripeptides and salt intake in 24-h ambulatory blood pressure measurements. Clin Exp Hypertens. 2010; 32(4):214-20. DOI: 10.3109/10641963.2010.491885. View

11.

Yoshizawa M, Maeda S, Miyaki A, Misono M, Choi Y, Shimojo N . Additive beneficial effects of lactotripeptides intake with regular exercise on endothelium-dependent dilatation in postmenopausal women. Am J Hypertens. 2010; 23(4):368-72. DOI: 10.1038/ajh.2009.270. View

12.

van Mierlo L, Koning M, van der Zander K, Draijer R . Lactotripeptides do not lower ambulatory blood pressure in untreated whites: results from 2 controlled multicenter crossover studies. Am J Clin Nutr. 2008; 89(2):617-23. DOI: 10.3945/ajcn.2008.26918. View

13.

Tomiyama H, Yamashina A . Arterial stiffness in prehypertension: a possible vicious cycle. J Cardiovasc Transl Res. 2012; 5(3):280-6. DOI: 10.1007/s12265-011-9345-4. View

14.

Misu Y, Yue J, Miyamae T, Goshima Y . Altered L-DOPA systems for blood pressure regulation in the lower brainstem of spontaneously hypertensive rats. Hypertens Res. 1995; 18(4):267-77. DOI: 10.1291/hypres.18.267. View

15.

Assadi F . Prehypertension: a warning sign of future cardiovascular risk. Int J Prev Med. 2014; 5(Suppl 1):S4-9. PMC: 3990920. View

16.

Egan B, Laken M . Pre-hypertension: rationale for pharmacotherapy. Curr Hypertens Rep. 2013; 15(6):669-75. DOI: 10.1007/s11906-013-0387-7. View

17.

Jakala P, Vapaatalo H . Antihypertensive Peptides from Milk Proteins. Pharmaceuticals (Basel). 2016; 3(1):251-272. PMC: 3991029. DOI: 10.3390/ph3010251. View

18.

Uhlig K, Patel K, Ip S, Kitsios G, Balk E . Self-measured blood pressure monitoring in the management of hypertension: a systematic review and meta-analysis. Ann Intern Med. 2013; 159(3):185-94. DOI: 10.7326/0003-4819-159-3-201308060-00008. View

19.

Cicero A, Colletti A, Rosticci M, Cagnati M, Urso R, Giovannini M . Effect of Lactotripeptides (Isoleucine-Proline-Proline/Valine-Proline-Proline) on Blood Pressure and Arterial Stiffness Changes in Subjects with Suboptimal Blood Pressure Control and Metabolic Syndrome: A Double-Blind, Randomized, Crossover Clinical.... Metab Syndr Relat Disord. 2015; 14(3):161-6. DOI: 10.1089/met.2015.0093. View

20.

Hollenberg N, Raij L . Angiotensin-converting enzyme inhibition and renal protection. An assessment of implications for therapy. Arch Intern Med. 1993; 153(21):2426-35. View

Effects of Lactotripeptide Supplementation on Tele-Monitored Home Blood Pressure and on Vascular and Renal Function in Prehypertension - Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study

Effects of Lactotripeptide Supplementation on Tele-Monitored Home Blood Pressure and on Vascular and Renal Function in Prehypertension　- Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study